IV Thiotepa — Competitive Intelligence Brief

IV Thiotepa (IV Thiotepa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alkylating agent. Area: Oncology.

phase 2 alkylating agent DNA Oncology Small molecule

Target snapshot

IV Thiotepa (IV Thiotepa) — Assistance Publique - Hôpitaux de Paris. Thiotepa is an alkylating agent that cross-links DNA, disrupting its structure and function, leading to cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Thiotepa TARGET	IV Thiotepa	Assistance Publique - Hôpitaux de Paris	phase 2	alkylating agent	DNA
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-05-14 — Vidaza · 12053482 · Method of Use · US
• 2029-05-14 — Vidaza · 11571436 · Formulation · US
• 2030-06-03 — Vidaza · 8846628 · Formulation · US

Sponsor landscape (alkylating agent class)

1. Alliance for Clinical Trials in Oncology · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Radiation Therapy Oncology Group · 1 drug in this class
4. Taizhou Hanzhong biomedical co. LTD · 1 drug in this class